- Home
- IMAB vs ALXO Comparison
IMAB vs ALXO Comparison
Compare IMAB & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ALXO
- Stock Information
- Founded
- IMAB 2014
- ALXO 2015
- Country
- IMAB United States
- ALXO United States
- Employees
- IMAB N/A
- ALXO N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- ALXO Health Care
- Exchange
- IMAB Nasdaq
- ALXO Nasdaq
- Market Cap
- IMAB 79.9M
- ALXO 76.5M
- IPO Year
- IMAB 2020
- ALXO 2020
- Fundamental
- Price
- IMAB $0.97
- ALXO $1.12
- Analyst Decision
- IMAB Strong Buy
- ALXO Buy
- Analyst Count
- IMAB 3
- ALXO 6
- Target Price
- IMAB $8.00
- ALXO $6.64
- AVG Volume (30 Days)
- IMAB 270.1K
- ALXO 775.3K
- Earning Date
- IMAB 03-13-2025
- ALXO 03-06-2025
- Dividend Yield
- IMAB N/A
- ALXO N/A
- EPS Growth
- IMAB N/A
- ALXO N/A
- EPS
- IMAB N/A
- ALXO N/A
- Revenue
- IMAB $569,464.00
- ALXO N/A
- Revenue This Year
- IMAB N/A
- ALXO N/A
- Revenue Next Year
- IMAB N/A
- ALXO N/A
- P/E Ratio
- IMAB N/A
- ALXO N/A
- Revenue Growth
- IMAB N/A
- ALXO N/A
- 52 Week Low
- IMAB $0.84
- ALXO $0.96
- 52 Week High
- IMAB $2.00
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- IMAB 46.51
- ALXO 38.53
- Support Level
- IMAB $0.96
- ALXO $1.00
- Resistance Level
- IMAB $1.04
- ALXO $1.22
- Average True Range (ATR)
- IMAB 0.05
- ALXO 0.09
- MACD
- IMAB -0.00
- ALXO 0.00
- Stochastic Oscillator
- IMAB 36.36
- ALXO 35.12
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.